Preclinical News and Research

RSS

Memory Pharmaceuticals issued key U.S. patent for series of nicotinic alpha-7 receptor agonists

Memory Pharmaceuticals Corp. has announced the issuance of U.S. Patent No. 7,429,664, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists.

27 Oct 2008

Targanta Therapeutics presents preclinical data on Oritavancin against Clostridium difficile infection

Targanta Therapeutics Corporation has released the in vivo data from a preclinical study comparing the activity of its antibiotic drug candidate, oritavancin, to vancomycin in a hamster model of Clostridium difficile infection.

26 Oct 2008

Quark Pharmaceuticals' siRNAs examined alone and in xombination with chemotherapy

Quark Pharmaceuticals, Inc. has announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008.

12 Oct 2008

Red wine cuts smokers risk for lung cancer

Cancer experts say drinking red wine may decrease the risk of lung cancer in men who smoke, because of its antioxidant properties.

7 Oct 2008

Exelixis files investigational new drug application for anticancer compound

Exelixis, Inc. announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL888, a novel anticancer compound. XL888 is an orally available small molecule inhibitor of HSP90, which is a chaperone protein that promotes the activity and stability of a range of key regulatory proteins, including kinases.

2 Oct 2008

Vitamin C supplements appear to undercut the effectiveness of cancer drugs

A new study by scientists in the United States has revealed that vitamin C may blunt the effectiveness of chemotherapy treatment.

1 Oct 2008

Array BioPharma presents positive data on its glucokinase activators in type 2 diabetes

Array BioPharma Inc. has announced the presentation of preclinical data on a novel small molecule glucokinase activator (GKA), ARRY-403, a drug for the treatment of Type 2 diabetes.

25 Sep 2008

Concert Pharmaceuticals initiates CTP-347 phase I clinical trial

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase I study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of CTP-347, a novel deuterium-containing serotonin modulator created by Concert researchers.

25 Sep 2008

Arana updates inflammatory pipeline milestones

Biotechnology company Arana Therapeutics Limited today provided an update on the major inflammatory compounds in its drug development pipeline. As part of this update, Arana said it has developed a new antibody candidate ART123, targeting inflammatory diseases and it plans to start a Phase I clinical trial for age-related macular degeneration (AMD) candidate PMX53 in 2009.

21 Sep 2008

S*BIO initiates trials of oral JAK2 inhibitor for hematological malignancies

S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma.

17 Sep 2008

Discovery of promising new chemotherapy target for a deadly form of leukemia

Cancer researchers at the Stanford University School of Medicine have discovered a promising new chemotherapy target for a deadly form of leukemia. Their discovery hinges on a novel "double agent" role for a molecular signal that regulates cell growth.

17 Sep 2008

Geron issued U.S. patent for cardiomyocytes from human embryonic stem cells

Geron Corporation has announced the issuance of U.S. Patent No. 7,425,448, with broad claims to cardiomyocytes derived from human embryonic stem cells (hESCs). The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron's GRNCM1 program is developing hESC-derived cardiomyocytes for the treatment of heart disease.

16 Sep 2008

Novel treatment for prostate cancer

Scientists at Sunnybrook Research Institute (SRI) are developing and commercializing a promising novel therapy for the treatment of prostate cancer that may offer patients a faster and more precise treatment than existing clinical alternatives, with fewer side effects.

15 Sep 2008

Inovio Biomedical achieves 75% complete response rate in preclinical testing of DNA-based cancer vaccine using its electroporation DNA delivery system

Inovio Biomedical Corporation announced today that it achieved positive results from its proprietary research and development program for DNA-based cancer vaccines delivered using the company's electroporation-based DNA delivery technology.

15 Sep 2008